
Mass cytometry analysis of B cells reveals distinct groups of activated and resting memory B cell populations. Credit: Nature Communications (2024). DOI: 10.1038/s41467-024-50997-4
Now, in a study published in Nature Communications, a team of researchers from Osaka University has pinpointed the B cells responsible for boosting COVID-19 immunity after vaccination.
“Several different types of B cells can be activated after vaccination, but it was not clear which B cells responded to the COVID-19 mRNA vaccine,” says lead author David Priest. “We found that blood from people who were vaccinated against COVID-19 contained activated atypical B cells. These B cells are the main responders to the vaccine because they are highly correlated with the serum antibody response against the COVID-19 virus.”
The team used a method called mass cytometry to examine and identify individual cells within the two known groups of B cells. These groups are classical B cells, which are common in human blood, and non-classical B cells. The newly discovered activated atypical cells fall into the non-classical group. The team also found these cells in the blood of patients who were infected with COVID-19.
“Activated atypical B cells provide a new way to assess how well people respond to COVID-19 vaccination. They also give us a new understanding of the underlying biology of mRNA vaccination,” explains senior author James Wing. “Now that we know these B cells are the primary responders to mRNA vaccines, we can work toward targeting them in future vaccine designs.”
With the help of this study, researchers may be able to develop improved updates to current COVID-19 vaccines as well as better candidate vaccines to help prevent future pandemics.
https://medicalxpress.com/news/2024-09-uncovering-specialized-immune-cells-covid.html

Check out our mRNA service to expedite your vaccine research
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
Related News
Navega Therapeutics Receives $4 Million CIRM Grant to Advance Epigenetic Gene Therapy for Chronic Pain
SAN DIEGO, CA – February 4, 2025 – Navega Therapeutics, a pioneering biotechnology company developing cutting-edge epigenetic gene therapies, today announced a significant milestone with the receipt of a $4 million Translational Science grant from the California...
Akribion Therapeutics Secures €8 Million in Seed Financing to Advance Novel RNA-Guided Cell Depletion Technology
ZWINGENBERG, Germany, February 4, 2025 – Akribion Therapeutics, a biotechnology company pioneering a unique, RNA-guided, nuclease-based technology for programmable cell depletion, today announced the closing of an €8 million Seed financing round. The round was led by...
UF-Kure19 CAR-T Cell Therapy Demonstrates High CR Rates, Low Toxicity in R/R NHL
Treatment with UF-Kure19, a rapidly manufactured CAR T-cell therapy, led to complete responses (CR) and low toxicity in patients with relapsed/refractory non-Hodgkin lymphoma, according to data from a single-arm, mult-center phase 1 study (NCT05400109) presented at...
Opinion: Companies Vie to Develop a Hunter Syndrome Therapy That Reaches the Brain
Several companies—including JCR Pharmaceuticals, Denali Therapeutics and Regenxbio—have products in the pipeline that could improve treatment options for this rare disease. Hunter syndrome is a rare, X‐linked disease caused by a deficiency of the lysosomal enzyme...
Related Services

AAV Packaging Services
READ MORE

Off-the-Shelf AAV Products
READ MORE